Consejo Superior de Investigaciones Científicas

Overcoming resistance to Beta-lactam antibiotics in Bacterial species

Posted by Consejo Superior de Investigaciones CientíficasResponsive · Patents for licensing · Spain

Summary of the technology

CSIC and the University of Würzburg have developed a new method to eliminate antibiotic-resistant
bacterial infections using classical antibiotics previously discarded due the occurrence of antibiotic
resistance.

Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent
licence agreement.

An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas
Consejo Superior de Investigaciones Científicas

Method to eliminate antibiotic-resistant bacterial infections


Colonia de Staphylococcus aureus MRSA The approach is the combination of B-lactam antibiotics with inhibitors of membrane microdomain formation in bacteria.
For the human pathogen MRSA resistant to penicillin and cephalosporin, the combination of penicillin with anti-microdomain compounds eliminate infections in animal models.
These anti-microdomain compounds are cholesterol-inhibitory drugs that are conventionally used to lower cholesterol in patients with hypercholesterolemia.
Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement.

Main innovations and advantages


· This method can be used to eliminate MRSA infections that areresistant to multiple antibiotics, which cause hard-to-treat infections inhospitals sometimes become lethal to the patient. As they are limitedstrategies to eliminate these infections, this method represents anoutstanding possibility to treat patients with complicated infections.
· This method can be used to recycle conventional antibiotics that werediscarded because of the spread of antibiotic resistance. Due to thelack of new antibiotics and the necessity to increase the arsenal to fightantibiotic resistance bacterial infections, recycling conventionalantibiotics to fight new multi-drug resistant infections is a promisingstrategy to reduce the number of infection in clinical settings.

Intellectual property status

Granted Patent
-
PCT patent application filed

Granted Patent
-
PCT patent application filed

Technology Owner

Consejo Superior de Investigaciones Científicas

Public Agency

Related keywords

  • Pharmaceutics
  • Biological Sciences
  • Medicine, Human Health
  • Medical Research
  • Pharmaceutical Products / Drugs
  • Virus, Virology / Antibiotics / Bacteriology
  • Biology / Biotechnology
  • Micro- and Nanotechnology related to Biological sciences
  • Industrial Biotechnology
  • Medical Health related
  • Surgical implants
  • Pharmaceuticals/fine chemicals
  • Clinical Medicine
  • Surgical instrumentation and equipment
  • Welfare technologies
  • Patient rehabilitation & training
  • mrsa

About Consejo Superior de Investigaciones Científicas

Public Agency from Spain

The Spanish National Research Council (in Spanish 'Consejo Superior de Investigaciones Científicas (CSIC)') is a government agency for basic and applied scientific research.

It is the largest public research organization in Spain, with presence in all the Autonomous Communities through 126 centers and 145 associated units.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.